INMD News and Press, InMode Ltd. From 01/31/23

Summary InMode Ltd. has 80%+ gross margins and 40%+ operating margins within a growing industry. The market is overestimating short-term worries that likely won't have a material effect on long-term cash flows. On both a relative basis and through a discounted cash flow, I estimate ...

Individual investors who want help picking stocks have more than a few options to choose from, including the recommendations of Wall Street analysts. Right now, InMode (NASDAQ: INMD) is a medical technology stock that analysts on Wall Street can't seem to get enough of. Among thos...

Some investors turned their backs on growth stocks as economic woes deepened last year. It's important to remember, though, that today's economic troubles and stock market downturn are temporary. Certain growth stocks may suffer in this sort of context. But they'll be among the first to rebound o...

As hundreds of growth stocks sold off amid rising interest rates and a tumultuous market in 2022, even strong operators were caught up in this drop's wake. This divergence between shorter-term movements, which are tied to quarterly earnings concerns versus a company's longer-term prospects, often...

There were two different stories for InMode (NASDAQ: INMD) in 2022. In the first half of the year, the medical device stock plunged 68%. However, in the second half, InMode roared back, with its shares soaring nearly 59% . Alas, it takes a bigger gain than that to make up for the ...

For thousands of years, people have sought to improve their physical appearances with all sorts of aesthetic interventions ranging from the banal to the bizarre. For a much shorter period of time, canny investors have been able to profit by placing their bets on the companies developing the most ...

If you're looking for stocks that can deliver explosive gains, the healthcare sector has you covered, Doximity (NYSE: DOCS) , TransMedics (NASDAQ: TMDX) , and InMode (NASDAQ: INMD) are leading the niche markets where they earn a living, but the stock market doesn't seem to...

Owning growth stocks in a bear market can be painful; fearful investors often flee to safety, and growth stocks, typically less proven or sometimes unprofitable, can become very unpopular on Wall Street. But the whims of the market don't necessarily mean that a stock can't be a good investment; g...

Shares of medical-device company InMode (NASDAQ: INMD) dropped on Wednesday after the company reported preliminary results for its upcoming fourth quarter. It also gave guidance for 2023. Both of these numbers looked good, but the stock was down nearly 10% Wednesday nonetheless. On Oc...

InMode ( NASDAQ: INMD ) rose ~6% pre-market as the medical technologies company said its Q4 revenue will be in the range of $133.2M to $133.4M, and FY22 revenue between $453.9M and $454.1M. The Q4 consensus revenue estimate is $129.45M and FY22 consensus stands at $448.71...